John Trizzino - 25 Jun 2023 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
EVP, CCO and CBO
Signature
/s/ John A. Herrmann III, Attorney-in-Fact
Issuer symbol
NVAX
Transactions as of
25 Jun 2023
Net transactions value
-$2,700
Form type
4
Filing time
27 Jun 2023, 16:32:40 UTC
Previous filing
14 Mar 2023
Next filing
22 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Options Exercise +833 +9.2% 9,893 25 Jun 2023 Direct F1
transaction NVAX Common Stock Tax liability $2,700 -403 -4.1% $6.70 9,490 25 Jun 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Restricted Stock Units Options Exercise $0 -833 -100% $0.000000* 0 25 Jun 2023 Common Stock 833 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2 The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the June 25, 2020 grant date, in each case subject to continued employment with the Company through such vesting date.